Biosimilar infliximab administration for the management of acute graft-versus-host disease
暂无分享,去创建一个
[1] L. Girandon,et al. Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells–Single Center Experience , 2018, Front. Bioeng. Biotechnol..
[2] H. Sengeløv,et al. Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival , 2018, Bone Marrow Transplantation.
[3] M. Patnaik,et al. Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] I. Tabbara,et al. Acute Graft Versus Host Disease: A Comprehensive Review. , 2017, Anticancer research.
[5] E. Deeks,et al. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases , 2016, BioDrugs.
[6] J. Wingard,et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[7] T. Luft,et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. , 2011, Blood.
[8] F. Awan,et al. Second allo-SCT from a different donor can improve severe steroid-resistant gut GVHD , 2010, Bone Marrow Transplantation.
[9] J. Perkins,et al. Infliximab for managing steroid-refractory acute graft-versus-host disease. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] K. McCaul,et al. Steroid Refractory Acute and Chronic Graft Versus Host Disease (GVHD) - Response to Photophoresis+/− Rituximab. , 2005 .
[11] B. Andersson,et al. Tumor necrosis factor- (cid:1) blockade for the treatment of acute GVHD , 2004 .
[12] B. Andersson,et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. , 2004, Blood.
[13] R. Fanin,et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. , 2004, Haematologica.
[14] M. Remberger,et al. Serum levels of cytokines correlate to donor chimerism and acute graft‐vs.‐host disease after haematopoietic stem cell transplantation , 2003, European journal of haematology.
[15] M. V. D. van den Brink,et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. , 2003, Blood.